BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 28011243)

  • 21. Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis.
    Pleva L; Kukla P; Zapletalova J; Hlinomaz O
    BMC Cardiovasc Disord; 2017 Jun; 17(1):168. PubMed ID: 28651572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: a pooled analysis from the SPIRIT II and SPIRIT III trials.
    Bartorelli AL; Serruys PW; Miquel-Hébert K; Yu S; Pierson W; Stone GW;
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):60-6. PubMed ID: 20578194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease.
    Costopoulos C; Latib A; Naganuma T; Sticchi A; Figini F; Basavarajaiah S; Carlino M; Chieffo A; Montorfano M; Naim C; Kawaguchi M; Giannini F; Colombo A
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1153-9. PubMed ID: 24262615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-eluting stents for the treatment of ostial coronary lesions: comparison of sirolimus-eluting stent with paclitaxel-eluting stent.
    Chen J; Li JJ; Chen JL; Qiao SB; Xu B; Yang YJ; Gao RL; Qin XW; Yuan JQ; Yao M; Wu YJ; Liu HB; Dai J; You SJ
    Coron Artery Dis; 2008 Nov; 19(7):507-11. PubMed ID: 18923247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Leon MB; Kandzari DE; Eisenstein EL; Anstrom KJ; Mauri L; Cutlip DE; Nikolsky E; O'Shaughnessy C; Overlie PA; Kirtane AJ; McLaurin BT; Solomon SL; Douglas JS; Popma JJ;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1208-18. PubMed ID: 20129547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.
    Chevalier B; Silber S; Park SJ; Garcia E; Schuler G; Suryapranata H; Koolen J; Hauptmann KE; Wijns W; Morice MC; Carrie D; van Es GA; Nagai H; Detiege D; Paunovic D; Serruys PW;
    Circ Cardiovasc Interv; 2009 Jun; 2(3):188-95. PubMed ID: 20031715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial.
    Kufner S; Joner M; Schneider S; Tölg R; Zrenner B; Repp J; Starkmann A; Xhepa E; Ibrahim T; Cassese S; Fusaro M; Ott I; Hengstenberg C; Schunkert H; Abdel-Wahab M; Laugwitz KL; Kastrati A; Byrne RA;
    JACC Cardiovasc Interv; 2017 Jul; 10(13):1332-1340. PubMed ID: 28683939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy and safety of drug-eluting balloons for the treatment of in-stent restenosis as compared with drug-eluting stents and with conventional balloon angioplasty.
    Oh PC; Suh SY; Kang WC; Lee K; Han SH; Ahn T; Shin EK
    Korean J Intern Med; 2016 May; 31(3):501-6. PubMed ID: 26951915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First results of the DEB-AMI (drug eluting balloon in acute ST-segment elevation myocardial infarction) trial: a multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic, intravascular, functional, and clinical outcomes.
    Belkacemi A; Agostoni P; Nathoe HM; Voskuil M; Shao C; Van Belle E; Wildbergh T; Politi L; Doevendans PA; Sangiorgi GM; Stella PR
    J Am Coll Cardiol; 2012 Jun; 59(25):2327-37. PubMed ID: 22503057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries.
    Wöhrle J; Werner GS
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):793-9. PubMed ID: 22511572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
    Jang SJ; Park DW; Kim WJ; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1106-14. PubMed ID: 22899589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of drug-eluting stent restenosis: Comparison between drug-eluting balloon versus second-generation drug-eluting stents from a retrospective observational study.
    Basavarajaiah S; Naganuma T; Latib A; Sticchi A; Ciconte G; Panoulas V; Chieffo A; Montorfano M; Carlino M; Colombo A
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):522-528. PubMed ID: 26715370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Twelve-month results of a paclitaxel releasing balloon in patients presenting with in-stent restenosis First-in-Man (PEPPER) trial.
    Hehrlein C; Dietz U; Kubica J; Jørgensen E; Hoffmann E; Naber C; Lesiak M; Schneider H; Wiemer M; Tölg R; Richardt G
    Cardiovasc Revasc Med; 2012; 13(5):260-4. PubMed ID: 22867706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of a paclitaxel coated balloon in combination with a bare metal stent on restenosis and endothelial function: comparison with a drug eluting stent and a bare metal stent.
    Clever YP; Cremers B; Speck U; Dietz U; Böhm M; Scheller B
    Catheter Cardiovasc Interv; 2014 Aug; 84(2):323-31. PubMed ID: 23996969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.
    Novack V; Cutlip D; Kleiman N; Pencina M; Mauri L; Yen CH; Berger P; Goldberg S; Kellett M; Waksman R; Hong M; Raizner AE; Cohen DJ
    JACC Cardiovasc Interv; 2009 Aug; 2(8):767-75. PubMed ID: 19695546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis.
    Seth A; Serruys PW; Lansky A; Hermiller J; Onuma Y; Miquel-Hebert K; Yu S; Veldhof S; Sood P; Sudhir K; Stone GW
    EuroIntervention; 2010 Feb; 5(7):788-94. PubMed ID: 20142192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Description of Pantera Lux paclitaxel-releasing balloon and preliminary quantitative coronary angiography (QCA) results at six months in patients with coronary in-stent restenosis.
    Hehrlein C; Richardt G; Wiemer M; Schneider H; Naber C; Hoffmann E; Dietz U
    EuroIntervention; 2011 May; 7 Suppl K():K119-24. PubMed ID: 22027721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: the LIPSIA Yukon trial.
    Desch S; Schloma D; Möbius-Winkler S; Erbs S; Gielen S; Linke A; Yu J; Lauer B; Kleinertz K; Dänschel W; Schuler G; Thiele H
    JACC Cardiovasc Interv; 2011 Apr; 4(4):452-9. PubMed ID: 21511226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent.
    Grube E; Schofer J; Hauptmann KE; Nickenig G; Curzen N; Allocco DJ; Dawkins KD
    JACC Cardiovasc Interv; 2010 Apr; 3(4):431-8. PubMed ID: 20398872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).
    Garg S; Serruys P; Onuma Y; Dorange C; Veldhof S; Miquel-Hébert K; Sudhir K; Boland J; Huber K; Garcia E; te Riele JA;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1190-8. PubMed ID: 20129545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.